1. Scrip
  2. >>Focus On Asia
  3. >>China

Chinese-Language Podcast: 聊聊七月生物制药热门话题

Hot Topic Chat

 
• By Brian Yang and Dexter Jie Yan

Join our China-based content team for this latest Chinese-language podcast episode discussing selected hot topics impacting the biopharma industry in China, including a homegrown COVID-19 antiviral approval, ADC deals and cross-strait tensions and their impact on the biotech sector. 

Chinese biotech podcast
CHINESE-LANGUAGE AUDIO CHAT ON RECENT HOT TOPICS IN CHINA'S BIOPHARMA SECTOR • Source: Shutterstock

Brian Yang and Dexter Yan discuss recent hot topics in China's biopharma industry in the latest episode of this new podcast series (Chinese-language description and story links below).

On 25 July, China approved the first domestically-originated oral antiviral for COVID-19, azvudine, developed by Henan Genuine Biotech. The approval marked the first homegrown competitor to Pfizer Inc.’s Paxlovid...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

Hengrui Set For Biggest Biopharma IPO So Far This Year

 
• By Dexter Jie Yan

Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

More from Focus On Asia